The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.
 
Pooja Advani
Stock and Other Ownership Interests - Abbvie (I); Alpha2 Pharmaceuticals (I); NanoString Technologies (I); Sorrento Therapeutics (I)
Honoraria - Ascentage Pharma Group (I); AstraZeneca (I); AstraZeneca (Inst); Epic Sciences; Epic Sciences; GE Healthcare; Menarini Group; OncLive/MJH Life Sciences
Consulting or Advisory Role - Ascentage Pharma (I); AstraZeneca (I); AstraZeneca (Inst); BMS (I); Breathe BioMedical; Puma Biotechnology
Speakers' Bureau - AstraZeneca (Inst); GE hea; Menarini
Research Funding - Ascentage Pharma (I); AstraZeneca (Inst); Atossa Therapeutics (Inst); Ayala Pharmaceuticals (Inst); biovica (Inst); Bristol Myer Squibb (I); Caris Life Sciences (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - patent pending on PCT-US2020-067237 (cancer vaccine platform) (I)
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus (I)
 
Sofia Braga
Travel, Accommodations, Expenses - AstraZeneca/Merck; Daiichi Sankyo; Gilead Sciences; Novartis
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Karthik Giridhar
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); MJH Live Events (Inst); MJH Live Events (Inst); NeoGenomics Laboratories (Inst); Puma Biotechnology (Inst); Tersera (Inst)
Research Funding - Guardant Health (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GRAIL; QuantumLeap Health
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Kelly McCann
Honoraria - OncLive/MJH Life Sciences; PER
Consulting or Advisory Role - Lilly; Puma Biotechnology; Tersera
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Olema Oncology (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
 
Ruth O'Regan
Honoraria - AstraZeneca/MedImmune; bioTheranostics; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; bioTheranostics; Lilly; Novartis; Puma Biotechnology; seagen
Research Funding - Novartis (Inst); Puma Biotechnology (Inst)
 
Cristina Saura Manich
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Exeter Pharmaceuticals; Pfizer; Phillips Health Works; Pierre Fabre; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; F. Hoffmann LaRoche; Gilead Sciences; Lilly; MediTech; Menarini; Menarini; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Debiopharm Group (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Janssen-Cilag SA (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merck Health KGAA, Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); SERVIER (Inst); Spanish Association Against Cancer Scientific Foundation and Cancer Research UK (Inst); Taiho Pharma USA Inc, (Inst)
Expert Testimony - AX`s consulting SARL; Boehringer Ingelheim; Bristol-Myers Squibb/Sanofi; Genentech; InnoUp; Merck Sharp and Dohme Spain; Novartis; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Puma Biotechnology; Roche; Seagen
 
Seth Wander
Consulting or Advisory Role - AstraZeneca; Biovica; Foundation Medicine; Genentech/Roche; Hologic; Lilly; Novartis; Pfizer; Puma Biotechnology; Regor Therapeutics; Veracyte
Speakers' Bureau - 2nd.MD; Guardant Health; Lilly
Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics; Sermonix Pharmaceuticals
 
Georg Bischof
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Beth Lowenthal
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Judith Bebchuk
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Lisa Eli
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Brian Barnett
Employment - Phoenix Molecular Designs
Stock and Other Ownership Interests - Phoenix Molecular Designs
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis; Roche
 
Tufia Haddad
Research Funding - Puma Biotechnology (Inst); Takeda (Inst)